Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Key Highlights
- ➤1-for-10 reverse split targets Nasdaq’s $1.00 minimum bid requirement
- ➤Shares projected to decline from approximately 10,331,116 million to 1,033,112 million
- ➤PRP Phase 1b First-In-Human study planned for up to 50 patients in Q1 2027
Expert Statements
James Nathanielsz, Chief Executive Officer of Propanc Biopharma
“The Reverse Stock Split is being implemented to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market and Nasdaq’s $1.00 minimum bid price requirement and support future growth plans.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma
“We are excited about the advancement of our lead asset, PRP, as we prepare for our Phase 1b, First-In-Human (FIH) study, in up to 50 advanced cancer patients with solid tumors in the first quarter of 2027.”
James Nathanielsz, Chief Executive Officer of Propanc Biopharma
“By undertaking this important corporate action, we will clear the pathway for execution of future R&D milestone events that we believe will be transformative for the Company and its shareholders.”
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that its Board of Directors, approved a 1-for-10 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (“Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of the open of the market October 26, 2026.
As a result of the Reverse Stock Split, every 10 pre-split shares of Company common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 10,331,116 million shares (as of October 8, 2026) to approximately 1,033,112 million shares on a pro forma basis. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per shareholder basis (per participant basis at DTC). The Reverse Stock Split will not affect the par value of the Company’s common stock.
Get started
Create a free account to read the full story.